Patents by Inventor Karl Edwin Griswold

Karl Edwin Griswold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11649291
    Abstract: Provided are variants of a chimeric anti-EGFR antibody. In various embodiments, the variants exhibit substantially improved thermostabilities and/or substantially higher levels of humanness, while retaining binding affinity near the parental level. The consistently high quality of the turnkey CoDAH designs, over a whole panel of variants, suggests that a computationally-directed approach encapsulates key determinants of antibody structure and function.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: May 16, 2023
    Assignee: Insmed Incorporated
    Inventors: Karl Edwin Griswold, Chris Bailey-Kellogg, Yoonjoo Choi
  • Publication number: 20200317792
    Abstract: Provided are variants of a chimeric anti-EGFR antibody. In various embodiments, the variants exhibit substantially improved thermostabilities and/or substantially higher levels of humanness, while retaining binding affinity near the parental level. The consistently high quality of the turnkey CoDAH designs, over a whole panel of variants, suggests that a computationally-directed approach encapsulates key determinants of antibody structure and function.
    Type: Application
    Filed: May 24, 2017
    Publication date: October 8, 2020
    Inventors: Karl Edwin GRISWOLD, Chris BAILEY-KELLOGG, Yoonjoo CHOI
  • Patent number: 9950041
    Abstract: The present invention is a genetically engineered version of a lysozyme protein wherein the engineered enzyme exhibits enhanced antimicrodial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge. Such an enzyme is an attractive therapeutic candidate for treating microbial or viral infections, particularly in cases where the infection results in an accumulation of polyanion inhibitors at the site of infection. Respiratory tract infections are one example of an infection where such an enzyme might be a particularly useful drug.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: April 24, 2018
    Inventors: Karl Edwin Griswold, Thomas Carr Scanlon
  • Publication number: 20170128546
    Abstract: The present invention is a genetically engineered version of a lysozyme protein wherein the engineered enzyme exhibits enhanced antimicrodial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge. Such an enzyme is an attractive therapeutic candidate for treating microbial or viral infections, particularly in cases where the infection results in an accumulation of polyanion inhibitors at the site of infection. Respiratory tract infections are one example of an infection where such an enzyme might be a particularly useful drug.
    Type: Application
    Filed: July 6, 2015
    Publication date: May 11, 2017
    Inventors: Karl Edwin Griswold, Thomas Carr Scanlon